Advertisement

Prehypertension and Vascular-Renal Impairment

  • Celine Dreyfuss-Tubiana
  • Michel E. Safar
  • Jacques Blacher
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

The concept of prehypertension has been developed in late 1930s following a series of studies showing a progressive increase of premature death from cardiovascular disease (CVD) in persons with blood pressure (BP) between 120 and 140 mmHg [1].

Keywords

Arterial stiffness Microalbuminuria Target organ damage Cardiovascular risk Renal risk 

References

  1. 1.
    Robinson SC, Brucer M. Range of normal blood pressure: a statistical and clinical study of 11,383 persons. Arch Intern Med. 1939;64:409–44.CrossRefGoogle Scholar
  2. 2.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–72.CrossRefGoogle Scholar
  3. 3.
    Albarwani S, Al-Siyabi S, Tanira MO. Prehypertension: underlying pathology and therapeutic options. World J Cardiol. 2014;6:728–43.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Tajeu GS, Booth JN, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O’Brien E, Oparil S, Ravenell JE, Safford MM, Seals SR, Shimbo D, Shea S, Spruill TM, Tanner RM, Muntner P. Incident cardiovascular disease among adults with blood pressure <140/90 mmHg. Circulation. 2017;136:798–812.  https://doi.org/10.1161/CIRCULATIONAHA.117.027362.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Jax TW. Metabolic memory: a vascular perspective. Cardiovasc Diabetol. 2010 Sep;9:51.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Dahl LK, Knudsen KD, Heine MA, Leitl GJ. Effects of chronic excess salt ingestion. Modification of experimental hypertension in the rat by variations in the diet. Circ Res. 1968;22:11–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Oguchi H, Sasamura H, Shinoda K, Morita S, Kono H, Nakagawa K, Ishiguro K, Hayashi K, Nakamura M, Azegami T, Oya M, Itoh H. Renal arteriolar injury by salt intake contributes to salt memory for the development of hypertension. Hypertension. 2014;64:784–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Lara LS, McCormack M, Semprum-Prieto LC, Shenouda S, Majid DS, Kobori H, Navar LG, Prieto MC. AT1 receptor-mediated augmentation of angiotensinogen, oxidative stress, and inflammation in ANG II-salt hypertension. Am J Physiol Renal Physiol. 2012;302:F85–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Kobori H, Nishiyama A, Abe Y, Navar LG. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension. 2003;41:592–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Susic D, Frohlich ED, Kobori H, Shao W, Seth D, Navar LG. Salt-induced renal injury in SHRs is mediated by AT1 receptor activation. J Hypertens. 2011;29:716–23.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lin L, Phillips WE, Manning RD. Intrarenal Angiotensin II is associated with inflammation, renal damage and dysfunction in Dahl salt-sensitive hypertension. J Am Soc Hypertens. 2009;3:306–14.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tenekecioglu E, Yilmaz M, Yontar OC, Karaagac K, Agca FV, Tutuncu A, Kuzeytemiz M, Bekler A, Senturk M, Aydin U, Demir S. Microalbuminuria in untreated prehypertension and hypertension without diabetes. Int J Clin Exp Med. 2014;7(10):3420–9.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Wang Q, Huang J, Sun Y, Zhang W, Gao Y, Yao W, Bian B, Li Y, Wu X, Niu K. Association of microalbuminuria with diabetes is stronger in people with prehypertension compared to those with ideal blood pressure. Nephrology (Carlton). 2017. [Epub ahead of print].  https://doi.org/10.1111/nep.13082.CrossRefPubMedGoogle Scholar
  14. 14.
    Jia CF, Jiang YN, Yang ZQ, Sun XX, Yu Y, Wang H, Lu Y, Chen AJ, Wang ZQ. Ascending aortic elasticity and related risk factors study on prehypertension patients. Am J Hypertens. 2017;30(1):61–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, Wu Y, Tang H, Xu D. Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J. 2014;167:160–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Papadopoulos D, Mourouzis I, Kotrotsou A, Papazachou U, Sanidas E, Tsioufis K, Makris T. Hemostasis parameters disturbances in healthy individuals with prehypertension. Clin Exp Hypertens. 2012;34:385–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Van Guilder GP. It is time to contend with the endothelial consequences of prehypertension. J Hum Hypertens. 2015;29(8):457.CrossRefPubMedGoogle Scholar
  18. 18.
    Garofalo C, Borrelli S, Pacilio M, Minutolo R, Chiodini P, De Nicola L, Conte G. Hypertension and prehypertension and prediction of development of decreased estimated GFR in the general population: a meta-analysis of cohort studies. Am J Kidney Dis. 2016;67:89–97.CrossRefPubMedGoogle Scholar
  19. 19.
    Huang Y, Cai X, Zhang J, Mai W, Wang S, Hu Y, Ren H, Xu D. Prehypertension and Incidence of ESRD: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63:76–83.CrossRefPubMedGoogle Scholar
  20. 20.
    Li Y, Xia P, Xu L, Wang Y, Chen L. A meta-analysis on prehypertension and chronic kidney disease. PLoS One. 2016;11:e0156575.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Nakaya H, Sasamura H, Hayashi M, Saruta T. Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol. 2001;12:659–66.PubMedGoogle Scholar
  22. 22.
    Nakaya H, Sasamura H, Mifune M, Shimizu-Hirota R, Kuroda M, Hayashi M, Saruta T. Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron. 2002;91:710–8.CrossRefPubMedGoogle Scholar
  23. 23.
    The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Heart, Lung, and Blood Institute; 1997. (NIH publication no. 98-4080).Google Scholar
  24. 24.
    The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med. 1997;157:657–67.CrossRefGoogle Scholar
  25. 25.
    Hypertension Prevention Trial Research Group. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Arch Intern Med. 1990;150:153–62.CrossRefGoogle Scholar
  26. 26.
    Jennings G, Nelson L, Nestel P, Esler M, Korner P, Burton D, Bazelmans J. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity. Circulation. 1986;73:30–40.CrossRefPubMedGoogle Scholar
  27. 27.
    Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R, et al. Treatment of mild hypertension: final results. JAMA. 1993;270:713–24.CrossRefPubMedGoogle Scholar
  28. 28.
    Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117–24.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347–504.CrossRefGoogle Scholar
  30. 30.
    Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468–74.CrossRefPubMedGoogle Scholar
  31. 31.
    Egan B, Panis R, Hinderliter A, Schork N, Julius S. Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension. J Clin Invest. 1987;80:812–7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Julius S, Nesbitt S, Egan B, Kaciroti N, Schork MA, Grozinski M, Michelson E, TROPHY Study Group. Trial of preventing hypertension: design and 2-year progress report. Hypertension. 2004;44:146–51.CrossRefPubMedGoogle Scholar
  33. 33.
    Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA. Feasibility of treating prehypertension with an angiotensin-receptor blocker. Trial of Preventing Hypertension (TROPHY) Study Investigators. N Engl J Med. 2006;354:1685–97.CrossRefGoogle Scholar
  34. 34.
    Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P, PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487–96.CrossRefGoogle Scholar
  35. 35.
    Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. HOPE-3 Investigators. N Engl J Med. 2016;374:2009–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Hassim Ismail N, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S, PURE (Prospective Urban Rural Epidemiology) Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959–68.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Celine Dreyfuss-Tubiana
    • 1
  • Michel E. Safar
    • 1
  • Jacques Blacher
    • 1
  1. 1.AP-HP, Diagnosis and Therapeutic CenterParis-Descartes University, Hôtel Dieu University HospitalParisFrance

Personalised recommendations